力生制药
(002393)
| 流通市值：59.53亿 | | | 总市值：61.28亿 |
| 流通股本：2.50亿 | | | 总股本：2.58亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 731,508,082.68 | 369,840,643.7 | 1,336,154,449.87 | 1,023,773,647.92 |
| 营业收入 | 731,508,082.68 | 369,840,643.7 | 1,336,154,449.87 | 1,023,773,647.92 |
| 二、营业总成本 | 619,756,337.76 | 305,793,020.68 | 1,211,524,253.09 | 903,119,117.83 |
| 营业成本 | 298,776,639.49 | 155,282,142.54 | 600,362,548.29 | 458,502,190.82 |
| 税金及附加 | 11,661,266.8 | 5,655,164.28 | 23,367,120.76 | 17,801,238.3 |
| 销售费用 | 222,721,274.04 | 109,950,272.82 | 367,081,919.78 | 284,786,816.83 |
| 管理费用 | 71,443,554.93 | 33,383,235.18 | 137,763,782.09 | 88,826,340.16 |
| 研发费用 | 59,994,195.46 | 30,749,905.79 | 126,543,443.67 | 93,864,571.85 |
| 财务费用 | -44,840,592.96 | -29,227,699.93 | -43,594,561.5 | -40,662,040.13 |
| 其中:利息费用 | 1,284,520.32 | 359,607.85 | 2,655,412.04 | 1,691,228.11 |
| 其中:利息收入 | 46,668,889.71 | 29,723,985.42 | 47,133,962.67 | 43,349,480.75 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -197,794.77 | 1,005,780.46 | 2,899,993.92 | 1,307,114 |
| 加:投资收益 | 315,674,594.19 | 1,092,821.86 | 100,178,648.73 | 76,807,083.51 |
| 资产处置收益 | 364,701.72 | -50,307.42 | -95,584.69 | 0 |
| 资产减值损失(新) | -16,435,037.58 | - | -15,251,452.39 | -228,112.05 |
| 信用减值损失(新) | 147,719.56 | - | 175,063.59 | -34,675.24 |
| 其他收益 | 2,678,401.67 | 1,120,873.56 | 9,113,854.28 | 2,902,098.97 |
| 四、营业利润 | 413,984,329.71 | 67,216,791.48 | 221,650,720.22 | 201,408,039.28 |
| 加:营业外收入 | 1,360,543.46 | 159,542.34 | 620,888.11 | 1,652,995.01 |
| 减:营业外支出 | 13,896,739.16 | 15,856.7 | 6,322,807.97 | 1,032,559.08 |
| 五、利润总额 | 401,448,134.01 | 67,360,477.12 | 215,948,800.36 | 202,028,475.21 |
| 减:所得税费用 | 56,110,667.64 | 10,789,532.07 | 29,987,975.53 | 33,694,028.45 |
| 六、净利润 | 345,337,466.37 | 56,570,945.05 | 185,960,824.83 | 168,334,446.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 345,337,466.37 | 56,570,945.05 | 185,960,824.83 | 168,334,446.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 342,923,994.39 | 55,275,346.71 | 184,528,445.53 | 169,252,412.9 |
| 少数股东损益 | 2,413,471.98 | 1,295,598.34 | 1,432,379.3 | -917,966.14 |
| 扣除非经常损益后的净利润 | 104,230,120.39 | 53,310,824.75 | 102,997,849.18 | 106,307,015.03 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.33 | 0.21 | 0.72 | 0.66 |
| (二)稀释每股收益 | 1.33 | 0.21 | 0.72 | 0.66 |
| 八、其他综合收益 | - | - | -174,730,748.26 | - |
| 归属于母公司股东的其他综合收益 | - | - | -174,730,748.26 | - |
| 九、综合收益总额 | 345,337,466.37 | 56,570,945.05 | 11,230,076.57 | 168,334,446.76 |
| 归属于母公司股东的综合收益总额 | 342,923,994.39 | 55,275,346.71 | 9,797,697.27 | 168,334,446.76 |
| 归属于少数股东的综合收益总额 | 2,413,471.98 | 1,295,598.34 | 1,432,379.3 | - |
| 公告日期 | 2025-08-22 | 2025-04-25 | 2025-03-21 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |